Chugai Seiyaku Kabushiki Kaisha

Japan Tobacco Inc.

Oncolys Biopharma, Inc.

Toshiyuki Sakai

Other

Sysmex Corporation

Chugai Research Institute for Molecular Medicine, Inc.

Sakai Toshiyuki

Naoko Fujita

Shinichi Kikuchi

Hiroyuki Abe

Tetsuya Iida

Mitsuru Takahashi

Takayuki Yamaguchi

Yoshikazu Hori

Hisashi Kawasaki

Kazuhide Hayakawa

Toyomichi Nanayama

Hironori Kurachi

Masahiro Tamaru

Takayuki Yoshida

Naoki Harada

Hideki Ishihara

Masahiro Sakaitani

Hitoshi Iikura

Hideji Fujii

Masayuki Matsushita

Fumio Watanabe

Sawako Ozawa

Toshihiro Aoki

Noriyuki Furuichi

Pil-Su Ho

Yasushi Tomii

Kenji Takanashi

Takamichi Sato

Ikumi Hyoudoh

Shigehide Kagaya

Yoshikazu Sukenaga

Naoko Ohtani

Hideki c/o Sysmex Corporation Ishihara

The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.

Pyrimidine compound and medical use thereof

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G, G, Gand Gare each independently selected from &#x2014;N&#x2550; etc., Ring Gis selected from divalent aryl etc., A is selected from amino etc., Gis selected from oxygen etc., Gis selected from oxygen etc., Gis selected from &#x2014;CH&#x2014; etc., and Ris selected from Calkyl etc.

p27 protein inducer

The inventors discovered for the first time the nucleotide sequence of the human DR5 gene promoter, the nucleotide sequence of the human Siah-1 gene promoter and what appear to be the core promoter regions thereof. The present invention further provides a screening method for substances which regulate promoter activity, comprising a step of bringing a test substance into contact with cells holding a vector which comprises this DNA together with a reporter gene ligated expressibly to this DNA, and a step of detecting changes in the expressed amount of the reporter gene due to contact with the test substance. This screening method is a method of very efficiently selecting anti-cancer drugs and the like.

DR5 gene promoter and SIAH-1 gene promoter

The present invention relates to a more accurate method of diagnosing cancer in a tissue or a cell by measuring the expression and activity of cell cycle related proteins and analyzing a cell cycle profile. In a cell cycle profile, at least two values of expression or activity of cell cycle related proteins are concurrently measured. The measurement of the cell cycle related protein is not limited as to the measurement method.

Molecular diagnostic method of a cancer tissue or a cancer cell

A 44-bp region that confers vitamin D-responsiveness to the human p27promoter in the human p27transcriptional regulatory mechanism was revealed. This region also conferred vitamin D-responsiveness to a heterogenous promoter. Moreover, it was found that vitamin Denhances the binding between the CCAAT box existing in the region and the NF-Y protein and also the binding between the Sp1 sequence (also existing in the region) and the Sp1 protein, thus inducing human p27transcription. Also revealed were methods of screening for pharmaceutical agents that regulate the expression of the p27gene using these molecular mechanisms.

[object Object]

In accordance with the present invention, there are provided a gene encoding the promoter region of a protein p51 which is capable of inducing cell death, and a gene encoding the 5'-untranslated region of p51. These genes are useful in diagnosing and treating diseases including cancer caused by abnormal regulation of cell propagation. Furthermore, in accordance with the present invention, there are provided the antisense DNAs and the antisense RNAs of these genes, nucleic acid probes comprising parts or all of these genes, methods of detecting the above genes of the present invention or analogous genes using the nucleic acid probes, transformants in which the above gene of the present invention has been introduced, and methods of screening drugs using them. These genes are also useful in diagnosing and treating diseases including cancer, etc.

Gene encoding promoter domain of tumor suppressor gene P51 and use thereof

The promoter of the human p27 gene is provided. The promoter region is useful to screen a compound that regulates the promoter of the human p27 gene or regulates the activity of the promoter. It enables the gene therapy utilizing the promoter.

Human p27Kip1 gene promoter

Human P27KIP1 gene promoter

The promoter of the human p27,gene is provided. The promoter region is useful to screen a compound that regulates the promoter of the human p27,gene or regulates the activity of the promoter. It enables the gene therapy utilizing the promoter.

Growing community of inventors

Kyoto, Japan

Toshiyuki Sakai